Capricor Therapeutics

203 articles about Capricor Therapeutics

• Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/14/2023

  Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

  11/7/2023

  Capricor Therapeutics will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023.

• Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

  10/19/2023

  Capricor Therapeutics announced that the Company will host a webinar with the nonprofit organization Parent Project Muscular Dystrophy to review key regulatory details and provide clinical updates that support the advancement of its ongoing HOPE-3, Phase 3 clinical trial of CAP-1002 for treating Duchenne muscular dystrophy.

• Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

  10/10/2023

  Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced data from two late-breaking posters presented at this year’s 28th International Annual Congress of the World Muscle Society (WMS) which took place in Charleston, South Carolina, from October 3-7, 2023.

• Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

  9/29/2023

  Capricor Therapeutics announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy.

• Capricor Therapeutics Announces $23 Million Registered Direct Offering

  9/29/2023

  Capricor Therapeutics announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering.

• Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

  9/6/2023

  Capricor Therapeutics today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately.

• Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/7/2023

  Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

  8/2/2023

  Capricor Therapeutics will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023.

• Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

  7/24/2023

  Capricor Therapeutics today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately.

• Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

  7/13/2023

  Capricor Therapeutics today announced the appointment of Paul Auwaerter, M.D. to its Board of Directors.

• Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

  6/30/2023

  Capricor Therapeutics (NASDAQ: CAPR) today announced positive 24-month safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).

• Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySafety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference

  6/13/2023

  Capricor Therapeutics announced that the Company will present 24-month safety and efficacy results from its ongoing HOPE-2 open-label extension study with its lead asset, CAP-1002, for the treatment of Duchenne Muscular Dystrophy at this year’s Parent Project Muscular Dystrophy Annual Conference.

• Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

  6/7/2023

  Capricor Therapeutics today announced an upcoming Type-B clinical meeting with the U.S. Food and Drug Administration (FDA), planned in early Q3 2023.

• Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/11/2023

  Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11, 2023

  5/4/2023

  Capricor Therapeutics will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023.

• Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

  4/27/2023

  Capricor Therapeutics announced the publication of a preclinical study in Microbiology Spectrum, a leading peer-reviewed scientific journal of the American Society for Microbiology, highlighting the therapeutic potential of its StealthX™ exosome platform technology to develop a multivalent vaccine against the spike and nucleocapsid SARS-CoV-2 proteins.

• Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

  3/23/2023

  Capricor Therapeutics announced today that the Company presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).

• Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/15/2023

  Capricor Therapeutics (NASDAQ: CAPR) announced today its financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

  3/8/2023

  Capricor Therapeutics will release its financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Wednesday, March 15, 2023.